incidence of gastroparesis with glp 1 New data links GLP-1 agonists for weight loss higher risk for pancreatitis, GI events GASTROPARESIS RISK IN PATIENTS WITH

FOR NOROVIRUS CAN BE SPREAD SOURCE: Centers for Disease Control and Prevention

Medical science has made such tremendous progress that there is hardly a healthy human left. Aldous Huxley GLP-1 Agonists at a Glance First-Generation (Short-Acting) Exenatide Byetta Lixisenatide Adlyxin / Lyxumia Second-Generation (Long-Acting) Exenatide ER Bydureon (weekly, now discontinued in some markets) Liraglutide Victoza (diabetes), Saxenda (obesity) Dulaglutide Trulicity Semaglutide Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral) Dual Agonist (GIP + GLP-1) Tirzepatide Mounjaro (diabetes), Zepbound (obesity) Triple or Combination Agonists (In Development) Retatrutide Triple agonist (GLP-1 + GIP + glucagon) CagriSema Combination of cagrilintide + semaglutide (GLP-1 + amylin analog) Orforglipron Oral, non-peptide GLP-1 receptor agonist (Eli Lilly) Danuglipron Oral small-molecule GLP-1 agonist (Pfizer) Efinopegdutide GLP-1/glucagon dual agonist (Merck/Biocon) AMG133 GLP-1 + GIP receptor modulator (Amgen)

Satoh K, Ouchi M, Morita A, and Kashimata M

Some diabetics are reportedly having trouble accessing their previously prescribed drugs